세계의 암 진단용 액체생검 시장 보고서(2025년)

Liquid biopsy for cancer diagnostics offers a less invasive alternative to traditional tissue biopsies, involving the assessment of genetic material or biomarkers found in a patient's blood or other bodily fluids to detect and monitor the presence of cancer. This approach is commonly utilized for screening and identifying non-small cell lung cancer (NSCLC) and is also employed as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

The main categories within liquid biopsy for cancer diagnostics encompass products and services. Products refer to procedures, methods, or tools designed or utilized for identifying illnesses or diseases in humans or other vertebrate animals. Various types of samples, such as blood, urine, and saliva, are utilized in this diagnostic approach. Liquid biopsy for cancer diagnostics is applicable to various types of cancer, including lung cancer, breast cancer, colon cancer, and others. The end-users for these diagnostics include hospitals, diagnostic centers, and other healthcare institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liquid biopsy for cancer diagnostics market statistics, including liquid biopsy for cancer diagnostics industry global market size, regional shares, competitors with a liquid biopsy for cancer diagnostics market share, detailed liquid biopsy for cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. This liquid biopsy for cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $9.23 billion in 2024 to $10.76 billion in 2025 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to advancements in genomic research, growing awareness of liquid biopsy benefits, increased prevalence of cancer, rise in demand for non-invasive cancer testing, expansion of precision medicine initiatives.

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $19.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to integration of liquid biopsy in routine cancer diagnostics, adoption of liquid biopsy for early cancer detection, expansion of cancer screening programs, growing focus on personalized medicine in oncology, increased funding for liquid biopsy research. Major trends in the forecast period include emergence of multi-omics liquid biopsy approaches, integration of artificial intelligence in liquid biopsy analysis, expansion of liquid biopsy applications beyond oncology, development of blood-based biomarkers for cancer, customization of liquid biopsy assays for specific cancer types.

The forecast of 15.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology care by inflating prices of next-generation sequencing platforms and bioinformatics software imported from Switzerland and Israel, resulting in postponed treatment decisions and higher precision medicine implementation costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is anticipated to drive the growth of the liquid biopsy market for cancer diagnostics in the future. Cancer encompasses a wide range of diseases that can arise in almost any organ or tissue in the body when abnormal cells grow uncontrollably, breach their typical boundaries, and either spread to other organs or invade adjacent tissues. This surge in cancer cases heightens the demand for diagnostic methods, such as early detection of cancer or tumor recurrence, patient risk assessment, and therapy monitoring. Liquid biopsy plays a crucial role by capturing tumor cells or their products released from primary or metastatic sites, offering comprehensive and real-time insights into tumor evolution, therapeutic targets, and mechanisms of treatment resistance. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, reported approximately 18.1 million cancer survivors in the United States, with projections suggesting this number will rise to 22.5 million by 2032. Furthermore, by 2040, the annual incidence of new cancer cases is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Thus, the increasing prevalence of cancer is propelling the growth of the liquid biopsy market for cancer diagnostics.

The rising demand for personalized medicine is expected to drive the growth of the liquid biopsy market for cancer diagnostics in the future. Personalized medicine represents a groundbreaking approach to healthcare that takes into account individual differences in patients' genetics, environments, and lifestyles. Liquid biopsy plays a crucial role in identifying specific genetic mutations and biomarkers linked to cancer, thereby enabling the development of tailored and targeted treatment strategies. For example, the Personalized Medicine Coalition, a U.S.-based professional membership organization, reported that in 2022, the approval of 12 new personalized medicines accounted for approximately 34% of all newly approved therapies, reflecting a significant increase from previous years. Consequently, the growing demand for personalized medicine is fueling the expansion of the liquid biopsy market for cancer diagnostics.

A prominent trend gaining traction is the focus on product innovations by major companies. These companies are strategically investing in the development of cutting-edge products to bolster their market position. An exemplar of this trend is BostonGene, a US-based biomedical software company, which introduced new liquid biopsy solutions in June 2023. These solutions aim to identify clinically relevant gene alterations, expanding the test portfolio and accelerating the development of novel assays, analytical tools, and pipelines. The innovative approach involves leveraging artificial intelligence-driven molecular and immunological profiling methodologies to analyze tumors, microenvironments, and host immunity. Notably, these solutions support immunotherapy treatment, provide insights into a patient's immune-related disorders, and enable the monitoring of disease progression and response to treatment.

Major players in the liquid biopsy for cancer diagnostics market are directing their efforts toward the development of advanced liquid biopsy assays. These assays, characterized by sophistication and refinement, analyze various components within liquid biological samples, such as blood or other bodily fluids. The objective is to detect and characterize specific biomarkers associated with cancer or other diseases. Illumina Inc., a global leader in DNA sequencing, exemplifies this focus on innovation. In November 2023, the company announced the launch of the 'TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)' research assay. This assay facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. Designed to streamline integration for users, the TSO 500 ctDNA v2 assay enhances the depth of insights available for cancer research.

In January 2022, when Exact Sciences Corp., a US-based molecular diagnostics company, acquired Thrive Earlier Detection Corp. for $2.15 billion. This strategic acquisition positions Exact Sciences Corp. to access clinical and regulatory teams, scale laboratory and IT capabilities, and advance blood-based, multi-cancer screening, aligning with evolving norms in cancer treatment. Thrive Earlier Detection Corp., known for its expertise in producing liquid biopsy tests, focuses on the early detection of multiple cancers.

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also include sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liquid Biopsy For Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liquid biopsy for cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liquid biopsy for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liquid biopsy for cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Product; Services
• 2) By Sample: Blood; Urine; Saliva
• 3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
• 4) By End-User: Hospitals; Diagnostic Centers; Other End-Users
• Subsegments:
• 1) By Product: Circulating Tumor Cells (CTCs) Detection Kits; Circulating Tumor DNA (ctDNA) Detection Kits; Exosome Isolation Kits; Sample Collection Devices
• 2) By Services: Testing Services; Analytical Services; Bioinformatics Services
• Companies Mentioned: F. Hoffman La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; The Menarini Group; Bio-Rad Laboratories Inc.; QIAGEN Inc.; Exact Sciences Corporation; Bio-Techne Corporation; ArcherDX Inc.; Neogenomics Laboratories Inc.; Guardant Health Inc.; Myriad Genetics Inc.; Foundation Medicine Inc.; Amoy Diagnostics Co. Ltd.; Biocartis Group NV; Biodesix Inc.; MDx Health Inc.; Sysmex Inostics Inc.; Biocept Inc.; Agena Bioscience Inc.; Laboratory for Advanced Medicine (LAM) Inc.; MiRXES Pte Ltd.; Inivata Limited; Resolution Bioscience Inc.; SAGA Diagnostics AB; NuProbe Inc.; Personal Gemone Diagnostics Inc.; Pathway Genomics Corporation; Angle PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liquid Biopsy For Cancer Diagnostics Market Characteristics

3. Liquid Biopsy For Cancer Diagnostics Market Trends And Strategies

4. Liquid Biopsy For Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Liquid Biopsy For Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liquid Biopsy For Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liquid Biopsy For Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Liquid Biopsy For Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liquid Biopsy For Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liquid Biopsy For Cancer Diagnostics Total Addressable Market (TAM)

6. Liquid Biopsy For Cancer Diagnostics Market Segmentation

• 6.1. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Product
• Services
• 6.2. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood
• Urine
• Salive
• 6.3. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colon Cancer
• Other Cancers
• 6.4. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Other End-Users
• 6.5. Global Liquid Biopsy For Cancer Diagnostics Market, Sub-Segmentation Of Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating Tumor Cells (CTCs) Detection Kits
• Circulating Tumor DNA (ctDNA) Detection Kits
• Exosome Isolation Kits
• Sample Collection Devices
• 6.6. Global Liquid Biopsy For Cancer Diagnostics Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing Services
• Analytical Services
• Bioinformatics Services

7. Liquid Biopsy For Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market

• 8.1. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liquid Biopsy For Cancer Diagnostics Market

• 9.1. China Liquid Biopsy For Cancer Diagnostics Market Overview
• 9.2. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liquid Biopsy For Cancer Diagnostics Market

• 10.1. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liquid Biopsy For Cancer Diagnostics Market

• 11.1. Japan Liquid Biopsy For Cancer Diagnostics Market Overview
• 11.2. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liquid Biopsy For Cancer Diagnostics Market

• 12.1. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liquid Biopsy For Cancer Diagnostics Market

• 13.1. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liquid Biopsy For Cancer Diagnostics Market

• 14.1. South Korea Liquid Biopsy For Cancer Diagnostics Market Overview
• 14.2. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liquid Biopsy For Cancer Diagnostics Market

• 15.1. Western Europe Liquid Biopsy For Cancer Diagnostics Market Overview
• 15.2. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liquid Biopsy For Cancer Diagnostics Market

• 16.1. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liquid Biopsy For Cancer Diagnostics Market

• 17.1. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liquid Biopsy For Cancer Diagnostics Market

• 18.1. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liquid Biopsy For Cancer Diagnostics Market

• 19.1. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liquid Biopsy For Cancer Diagnostics Market

• 20.1. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market

• 21.1. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liquid Biopsy For Cancer Diagnostics Market

• 22.1. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liquid Biopsy For Cancer Diagnostics Market

• 23.1. North America Liquid Biopsy For Cancer Diagnostics Market Overview
• 23.2. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liquid Biopsy For Cancer Diagnostics Market

• 24.1. USA Liquid Biopsy For Cancer Diagnostics Market Overview
• 24.2. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liquid Biopsy For Cancer Diagnostics Market

• 25.1. Canada Liquid Biopsy For Cancer Diagnostics Market Overview
• 25.2. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liquid Biopsy For Cancer Diagnostics Market

• 26.1. South America Liquid Biopsy For Cancer Diagnostics Market Overview
• 26.2. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liquid Biopsy For Cancer Diagnostics Market

• 27.1. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liquid Biopsy For Cancer Diagnostics Market

• 28.1. Middle East Liquid Biopsy For Cancer Diagnostics Market Overview
• 28.2. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liquid Biopsy For Cancer Diagnostics Market

• 29.1. Africa Liquid Biopsy For Cancer Diagnostics Market Overview
• 29.2. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape
• 30.2. Liquid Biopsy For Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffman La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Menarini Group Overview, Products and Services, Strategy and Financial Analysis

31. Liquid Biopsy For Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Bio-Rad Laboratories Inc.
• 31.2. QIAGEN Inc.
• 31.3. Exact Sciences Corporation
• 31.4. Bio-Techne Corporation
• 31.5. ArcherDX Inc.
• 31.6. Neogenomics Laboratories Inc.
• 31.7. Guardant Health Inc.
• 31.8. Myriad Genetics Inc.
• 31.9. Foundation Medicine Inc.
• 31.10. Amoy Diagnostics Co. Ltd.
• 31.11. Biocartis Group NV
• 31.12. Biodesix Inc.
• 31.13. MDx Health Inc.
• 31.14. Sysmex Inostics Inc.
• 31.15. Biocept Inc.

32. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liquid Biopsy For Cancer Diagnostics Market

34. Recent Developments In The Liquid Biopsy For Cancer Diagnostics Market

35. Liquid Biopsy For Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer